Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced that CEO Eric Dobmeier will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced that CEO Eric Dobmeier will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 PM ET. The event will include 1x1 meetings with management. Interested parties can access the live webcast and archived recordings on Chinook's Investors website for 90 days after the event. Chinook specializes in precision medicines for kidney diseases, with ongoing clinical trials for products like atrasentan and BION-1301.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was +3.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive officer of Chinook Therapeutics, is scheduled to present and participate with management in 1x1 meetings at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 pm ET.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.